Passage Bio, Inc. (NASDAQ:PASG) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET

Company Participants

Stuart Henderson - Vice President of Corporate Development and Investor Relations

Bruce Goldsmith - President and CEO

Eliseo Salinas - Chief Research and Development Officer

Simona King - Chief Financial Officer

Conference Call Participants

Madhu Kumar - Goldman Sachs

Tessa Romero - JPMorgan

Neena Bitritto-Garg - Citi

Brendan Smith - Cowen & Company

Daniel Brill - Raymond James

Operator

Thank you for holding. Good morning, and welcome to the Passage Bio First Quarter 2022 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that this call is being recorded at the Company’s request.

At this time, I’d like to turn the call over to Stuart Henderson, Vice President of Corporate Development and Investor Relations. Stuart, please proceed.

Stuart Henderson

Thank you, operator. This morning, we issued a press release that outlines the topics we plan to discuss today. This release is available on the Passage Bio website under the Press Releases and Statements section of Investors and News.

On today’s call, Bruce Goldsmith, President and Chief Executive Officer, will review our first quarter 2022 and recent business highlights. And Simona King, our Chief Financial Officer, will review our first quarter 2022 financial results.

Before we begin, please note that today’s call may include a number of forward-looking statements, including, but not limited to, comments on our expectations about timing and execution of anticipated milestones, including the initiation of clinical trials and the availability of clinical data from such trials; our expectations about our collaborators and partners’ ability to execute key initiatives; the ability of our lead product candidates to treat their respective target CNS disorder; manufacturing plans and strategies; trends with respect to financial performance and cash flows; the Company’s ability to fund research and development programs; impacts of the COVID-19 pandemic on the Company’s operations; and its ability to manage costs, along with uses of cash and other matters.

These forward-looking statements are based on assumptions that are subject to risks and uncertainties that could cause the Company’s actual results to differ significantly from those suggested by these statements. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements.

Please refer to the Company’s filings with the SEC for information concerning risk factors that could cause actual results to differ materially from expectations, including any forward-looking statements made on this call. Except as required by law, the Company disclaims any obligation to publicly update or revise any forward-looking statements to account for or reflect events or circumstances that occur after this call.